ProHost Biotech
Login
Members Home
Home
News & Comments
About Us
Forward Looking Statement
Contact Us
Statement
News and Comments
BIOTECHNOLOGY: ON THE WAY TO MEETING HIGHLY AMBITIOUS EXPECTATIONS
Wednesday, September 05, 2012
More...
Comments (0)
|
Trackbacks (0)
|
Permalink
Previous
1
Next
Recent Posts
THE REAL VALUE OF SEATTLE GENETICS
SAREPTA: What's Going On ?
ImmunoGen Offers New Hopes For Treatment Of Subtypes Of Squamous Cell Carcinomas And Other Difficult-To-Treat Cancers
A Quick Response To ARIAD'S (ARIA) Conference Call
NORTHWEST BIOTHERAPEUTICS: AN EXAMPLE OF REFORM IN THE DRUG APPROVAL PROCESS.
IDERA (IDRA): GOOD NEWS OFFSET SOMEWHAT BY SKEPTICISM NOT PESSIMISM
Biogen Idec Pays Elan $3.25 billion For Tysabri. Do We Leave, Or Stay?
The FDA Approval Of Kynamro™ Promises ISIS A Bright Future Read Also about ALNY; Sarepta, SNY
XOMA: WILL THE LOVE-HATE SKEPTICISM MARRIAGE WITH INVESTORS FINALLY ENDS UP IN A STABLE RELATIONSHIP?
THERAVANCE: BECAME TEMPTING TO INVESTORS ANR TO ITS PARTNER
Abbott Laboratories (ABT)
(1)
ADVENTRIX (ANX)
(1)
Alnylam (ALNY)
(3)
Amgen (AMGN)
(8)
Anadys (ANDS)
(1)
Ariad (ARIA)
(6)
Array Pharmaceuticals (ARRY)
(1)
Benlysta (belimumab)
(1)
Biogen Idec (BIIB)
(2)
Bristol-Myers Squibb (BMY)
(2)
CompuGen (CGEN)
(4)
Cytokinetics (CYTK)
(2)
Dendreon (DNDN)
(7)
Dynavax (DVAX)
(1)
Elan (ELN)
(6)
Endometrial Cancer
(1)
Exelixis (EXEL)
(4)
Genentech
(2)
Gilead (GILD)
(6)
GlaxoSmithKline (GSK)
(2)
Herceptin
(2)
Human Genome Sciences (HGSI)
(2)
Idenix (IDIX)
(2)
IDERA (IDRA)
(1)
Illumina (ILMN)
(4)
ImmunoGen (IMGN)
(10)
Incyte (INCY)
(3)
Intermune (ITMN)
(2)
ISIS (ISIS)
(3)
KERYX (KERX)
(1)
Merck (MRK)
(3)
Micromet (MITI)
(1)
Multiple Myeloma
(1)
Onyx (ONXX)
(4)
OSI (OSIP)
(1)
Pluristem (PSTI)
(1)
Prolor Biotech (PBTH)
(2)
Rapamune
(1)
Regeneron (REGN)
(7)
Revlimid (lenolidamide)
(1)
Ridaforolimus
(1)
Roche (RHHBY)
(2)
Roche (ROCHE)
(1)
Sangamo (SGMO)
(2)
Sanofi (SNA)
(1)
Sanofi (SNY)
(1)
Sanofi-Aventis (SAN)
(2)
Sarepta (SRPT)
(2)
Seattle Genetics (SGEN)
(6)
Sequenom (SQNM)
(7)
SUNESIS PHARMACEUTICALS (SNSS)
(1)
Telaprevir
(1)
Theravance (THRX)
(1)
Trastuzumab-DM1
(1)
Tysabri
(1)
Valeant Pharmaceuticals International (VRX)
(1)
Velcade (bortezomib)
(1)
Vertex (VRTX)
(10)
Xoma (XOMA)
(5)
ZALTRAP™
(1)
Zerenex
(1)
Archive
May 2013 (1)
April 2013 (3)
March 2013 (2)
February 2013 (1)
January 2013 (3)
December 2012 (4)
November 2012 (2)
October 2012 (1)
September 2012 (2)
August 2012 (3)
July 2012 (1)
June 2012 (3)
Tags
Illumina (ILMN)
Anadys (ANDS)
Sanofi (SNA)
Multiple Myeloma
Regeneron (REGN)
ADVENTRIX (ANX)
Array Pharmaceuticals (ARRY)
Telaprevir
Incyte (INCY)
GlaxoSmithKline (GSK)
Seattle Genetics (SGEN)
Alnylam (ALNY)
Sequenom (SQNM)
Merck (MRK)
Dendreon (DNDN)
Sanofi-Aventis (SAN)
Elan (ELN)
Vertex (VRTX)
Trastuzumab-DM1
Roche (RHHBY)
ImmunoGen (IMGN)
Ariad (ARIA)
Human Genome Sciences (HGSI)
Pluristem (PSTI)
OSI (OSIP)
Idenix (IDIX)
IDERA (IDRA)
Exelixis (EXEL)
Biogen Idec (BIIB)
Prolor Biotech (PBTH)
Valeant Pharmaceuticals International (VRX)
Intermune (ITMN)
Amgen (AMGN)
Herceptin
Sanofi (SNY)
Benlysta (belimumab)
Endometrial Cancer
KERYX (KERX)
Velcade (bortezomib)
Micromet (MITI)
Abbott Laboratories (ABT)
Rapamune
Ridaforolimus
Onyx (ONXX)
Dynavax (DVAX)
Sarepta (SRPT)
Xoma (XOMA)
Gilead (GILD)
Sangamo (SGMO)
SUNESIS PHARMACEUTICALS (SNSS)
Revlimid (lenolidamide)
Roche (ROCHE)
ISIS (ISIS)
Genentech
CompuGen (CGEN)
Zerenex
Theravance (THRX)
Cytokinetics (CYTK)
Bristol-Myers Squibb (BMY)
Tysabri
ZALTRAP™
SECURE ZONE LOGIN
Username
Password
Remember Me